Abstract
Background
1,25-dihydroxy-22-ovavitamin D3 (22-oxacalcitriol, OCT) was recently introduced commercially as an analogue of 1,25 (OH)2 vitamin D3, but one which has less pronounced calcemic activity.
Methods
To examine the efficacy and tolerability of OCT, 46 hemodialysis patients with secondary hyperparathyroidism were randomly assigned to receive either intravenous OCT or oral calcitriol pulse therapies. The patients were monitored for serum calcium, phosphate, intact parathyroid hormone (PTH), and bone alkaline phosphatase (BAP) for 24 weeks. The efficacy of intravenous OCT was also examined in 24 additional patients who were refractory to oral calcitriol pulse therapy.
Results
In the randomized trial, intact PTH levels were significantly suppressed within 4 weeks after the initiation of each therapy, and this effect was well maintained thereafter in both treatment groups. While intact PTH was significantly lower at 4 weeks in the calcitriol pulse group than in the OCT group (P = 0.02), no statistical differences were observed during later treatment periods. BAP was reduced equally by each treatment. At 4 weeks (P = 0.02) and thereafter (P = 0.06), serum calcium was higher among calcitriol-treated patients than among those who received OCT treatment. Eight of 24 patients who were refractory to oral calcitriol pulse therapy responded to intravenous OCT. The patients who responded tended to have lower serum intact PTH and phosphorus levels and smaller parathyroid glands at the start of OCT treatment than nonresponders.
Conclusions
OCT is as effective as oral calcitriol pulse therapy in suppressing intact PTH and BAP in chronic hemodialysis patients. It was confirmed that OCT exhibits less calcemic activity than calcitriol. Moreover, under certain conditions, switching to OCT may help in the treatment of hyperparathyroidism, which is refractory to conventional oral calcitriol pulse therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
KA Hruska SL Teitelbaum (1995) ArticleTitleRenal osteodystrophy N Engl J Med 333 166–74 Occurrence Handle10.1056/NEJM199507203330307 Occurrence Handle7791820
E Slatopolsky C Weerts J Thielan et al. (1984) ArticleTitleMarked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients J Clin Invest 74 2136–43 Occurrence Handle6549016
Y Tsukamoto M Nomura Y Takahashi et al. (1991) ArticleTitleThe “oral 1,25-dihydroxyvitamin D3 pulse therapy” in hemodialysis patients with severe secondary hyperparathyroidism Nephron 57 23–8 Occurrence Handle2046811
LD Quarles DA Yohay BA Carroll et al. (1994) ArticleTitleProspective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD Kidney Int 45 1710–21 Occurrence Handle7933819
BS Levine M Song (1996) ArticleTitlePharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients J Am Soc Nephrol 7 488–96 Occurrence Handle8704116
G Bacchini F Fabrizi G Pontoriero et al. (1997) ArticleTitle“Pulse oral” versus intravenous calcitriol therapy in chronic hemodialysis patients Nephron 77 267–72 Occurrence Handle9375818
AJ Brown CR Ritter JL Finch et al. (1989) ArticleTitleThe noncalcemic analogue of vitamin D, 22-oxacalcitol, suppresses parathyroid hormone synthesis and secretion J Clin Invest 84 728–32 Occurrence Handle2760211
M Kubrusly ER Gagne P Urena et al. (1993) ArticleTitleEffect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism Kidney Int 44 551–6 Occurrence Handle8231027
Y Tsukamoto M Hanaoka T Matsuo et al. (2000) ArticleTitleEffect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism Am J Kidney Dis 35 458–64 Occurrence Handle10692271
T Akizawa M Suzuki T Akiba et al. (2001) ArticleTitleClinical effects of Maxacalcitol on secondary hyperparathyroidism of uremic patients Am J Kidney Dis 38 S147–S151 Occurrence Handle11576942
T Shigematsu Y Kawaguchi S Unemura et al. (1993) ArticleTitleSuppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol Intern Med 32 695–701 Occurrence Handle8142673
M Teng M Wolf E Lowrie et al. (2003) ArticleTitleSurvival of patients undergoing hemodialysis with paricalcitriol or calcitriol therapy N Engl J Med 349 446–56 Occurrence Handle10.1056/NEJMoa022536 Occurrence Handle12890843
GA Block TE Hulbert-Shearon NW Levin et al. (1998) ArticleTitleAssociation of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 607–18 Occurrence Handle9531176
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S77–S84
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tamura, S., Ueki, K., Mashimo, K. et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 9, 238–243 (2005). https://doi.org/10.1007/s10157-005-0363-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10157-005-0363-x